Ireland
--:--IST
Priya Life Science Sponsor trial record
Sponsor · clinical trials

Enveda Therapeutics clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine and the EU Clinical Trials Information System (CTIS) — current trials in our USA and EU (CTIS) registers with Enveda Therapeutics as lead sponsor. Synced 12 Nov 2026
4Current trials
3Recruiting now
1Drug in these trials
2Trial registers
At a glance

Enveda Therapeutics is the lead sponsor of 4 current clinical trials in our USA and EU (CTIS) registers. 3 are recruiting patients now. All registered phases are Phase 2. The drugs named most often in its trials are ENV-294. The most-studied condition is Asthma.

ClinicalTrials.gov trials by status

  • Recruiting3100%

Trials by phase

  • Phase 23100%
01

Clinical trials sponsored by Enveda Therapeutics

3 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
ENV-294 for Moderate-to-Severe Asthma: A 12-Week Study in Adults
NCT07301255 · Asthma
Drug: ENV-294
Phase 2 Recruiting 2026-01 USA
A Phase 2b Dose-Ranging Study to Evaluate the Efficacy and Safety of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
NCT07643766 · Atopic Dermatitis
Drug: ENV-294
Phase 2 Recruiting 2026-06 USA
Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
NCT07298395 · Atopic Dermatitis (AD)
Drug: ENV-294
Phase 2 Recruiting 2025-12 USA

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Enveda Therapeutics in the EU trials register (CTIS)

1 trial

Authorised or ongoing trials in the EU Clinical Trials Information System with Enveda Therapeutics as sponsor. Some are the same study as a ClinicalTrials.gov record above; the two registries share no common ID. Trials with a site in Ireland are listed first.

StudyPhaseStatusCountries
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy and Safety of ENV-294 in Adult Participants with Moderate-to-Severe Atopic Dermatitis
2026-526184-38-00 · Skin and Connective Tissue Diseases
Drug: ENV-294
Phase 2 Authorised Germany, Czechia, Bulgaria + 2 more
03

Drugs in Enveda Therapeutics trials

1 compound

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

04

Conditions in Enveda Therapeutics trials

3 conditions
05

By trial register

RegisterTrialsRecruiting
Clinical trials in USA33
EU register (CTIS)1—

A trial with sites in more than one country appears in each of those registers.

06

Other sponsors in Asthma

SponsorTrials
AstraZeneca13
GlaxoSmithKline12
Chiesi Farmaceutici4
University College, London3
McMaster University3
Sunshine Guojian Pharmaceutical (Shanghai)2
First Affiliated Hospital of Ningbo University2
Guangdong Hengrui Pharmaceutical2
Taichung Veterans General Hospital2
Copenhagen Studies on Asthma in Childhood2

Sponsors with the most current trials registered for this condition.

07

Questions about Enveda Therapeutics trials

How many clinical trials does Enveda Therapeutics sponsor?

Enveda Therapeutics is the lead sponsor of 3 current trials on ClinicalTrials.gov in our USA register, and 1 authorised or ongoing trial in the EU register (CTIS), as of the registry sync on 12 November 2026. Completed and withdrawn studies are not counted.

Are Enveda Therapeutics trials recruiting?

Yes. 3 of its 3 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Enveda Therapeutics testing?

Its current trials name 1 drug or biological as interventions. The most frequent are ENV-294 (4). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 12 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.